Pomerantz LLP is investigating AstraZeneca and some of its executives for potential securities fraud following the failure of the Phase-3 CARDIO-TTransform trial for Wainua, a treatment for amyloid cardiomyopathy. The trial did not meet its primary endpoint, causing AstraZeneca's stock to drop 5.7% on July 9, 2026. The investigation aims to determine if AstraZeneca engaged in unlawful business practices. Investors affected by the stock decline are encouraged to contact Pomerantz LLP for potential class action participation.
Deutsche Bank acknowledged positive data from AstraZeneca's tozorakimab for chronic obstructive pulmonary disease (COPD), presented at the ERS conference, supporting the drug's commercial potential. Despite this, the bank maintained a 'sell' rating o...
AstraZeneca's phase III trial results for tozorakimab in treating chronic obstructive pulmonary disease (COPD) showed significant reduction in flare-ups, especially in former smokers. The drug met its primary endpoint with a 29% to 34% reduction in e...
Amgen's Phase 3 DeLLphi-305 study demonstrated that IMDELLTRA (tarlatamab-dlle) combined with AstraZeneca's durvalumab significantly improves overall survival, progression-free survival, and response rates compared to durvalumab alone in patients wit...
AstraZeneca released full data from two late-stage trials of its experimental COPD drug, tozorakimab, showing significant reduction in flare-ups among both former and current smokers. The drug, under FDA priority review with expected approval in earl...
AstraZeneca's drug Etcamah (camizestrant) received accelerated FDA approval for use with CDK4/6 inhibitors in hormone receptor positive, HER2 negative metastatic breast cancer patients with ESR1 mutations. This approval follows earlier European clear...
